Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

2-amino-N'-benzylideneacetohydrazides and Derivatives for the Management of CFTR Protein Mediated Diseases

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • Publication Date:
    May 7, 2020
  • معلومة اضافية
    • Document Number:
      20200138752
    • Appl. No:
      16/734213
    • Application Filed:
      January 03, 2020
    • نبذة مختصرة :
      This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N′-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N′-benzylidene-acetohydrazide compound is ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    • Claim:
      1. A method of treating chronic obstructive pulmonary disease comprising administering an effective amount of ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide or salt thereof to a subject wherein the subject is diagnosed with chronic obstructive pulmonary disease.
    • Claim:
      2. The method of claim 1 wherein ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide or salt thereof is administered in combination with an antibiotic.
    • Claim:
      3. The method of claim 2 wherein the antibiotic is colistin, clavulanate, aztreonam, ceftazidime, ciprofloxacin, gentamicin, tobramycin, salt or combination thereof.
    • Claim:
      4. The method of claim 1 wherein ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide or salt thereof is administered in combination with a bronchodilator.
    • Claim:
      5. The method of claim 4 wherein the bronchodilator is salbutamol, albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine, ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuterol, indacaterol, theophylline, tiotropium, ipratropium, salt or combinations thereof.
    • Claim:
      6. A method of treating chronic obstructive pulmonary disease comprising administering an effective amount of ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide or salt thereof to a subject wherein the subject is diagnosed with chronic obstructive pulmonary disease.
    • Claim:
      7. The method of claim 6 wherein ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide or salt thereof is administered in combination with an antibiotic.
    • Claim:
      8. The method of claim 7 wherein the antibiotic is colistin, clavulanate, aztreonam, ceftazidime, ciprofloxacin, gentamicin, tobramycin, salt or combination thereof.
    • Claim:
      9. The method of claim 6 wherein ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide or salt thereof is administered in combination with a bronchodilator.
    • Claim:
      10. The method of claim 9 wherein the bronchodilator is salbutamol, albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine, ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuterol, indacaterol, theophylline, tiotropium, ipratropium, salt or combinations thereof.
    • Current International Class:
      61; 61; 07; 61
    • الرقم المعرف:
      edspap.20200138752